Review



anti p65 rabbit antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Proteintech anti p65 rabbit antibody

    Anti P65 Rabbit Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1284 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+p65/NF-%CE%BAB+p65+Polyclonal+antibody/pmc13657245-66-0-4
    Average 96 stars, based on 1284 article reviews
    anti p65 rabbit antibody - by Bioz Stars, 2026-10
    96/100 stars

    Images

    1) Product Images from "M2 type tumor-associated macrophage-derived CCL-18 promotes glioma cell proliferation but does not mediates glioma recurrence after radiotherapy"

    Article Title: M2 type tumor-associated macrophage-derived CCL-18 promotes glioma cell proliferation but does not mediates glioma recurrence after radiotherapy

    Journal: iScience

    doi: 10.1016/j.isci.2026.117695


    Figure Legend Snippet:

    Techniques Used: Cell-Signaling, Virus, Tissue, Microarray, Recombinant, cDNA Synthesis, Enzyme-linked Immunosorbent Assay, Software, Biomarker Discovery, In Vivo Imaging

    Related Articles

    Incubation:

    Article Title: Multi-omics insights into dietary zinc–mediated reprogramming of the gut–nasal ecosystem in allergic rhinitis
    Article Snippet: .. As mentioned previously , the prepared 4μm nasal mucosal and colon sections were incubated with primary antibodies including anti-p65 (80979-1-RR, diluted 1:350, proteintech), anti-GPR43 (19952-1-AP, diluted 1:350, proteintech), anti-ZO-1 (ER41204, diluted 1:1,500, huabio), and anti-Occludin (ET1701-76, diluted 1:500, huabio), and then added with corresponding secondary IgG (SA00003-2, diluted 1:350, proteintech), subjected to immunofluorescence (IF) analysis. .. Images were acquired using a Apexview APX100 all-in-one microscope (Olympus, Japan) and a shengqiang SQS-120P Slide Scanner (shengqiang, China).

    Article Title: Autophagy promotes the brain metastasis of cisplatin-resistant lung cancer cells through the KLF4/KLF2/IL15 signaling pathway.
    Article Snippet: .. The membrane was blocked and incubated with the following diluted primary antibodies overnight at 4°C: anti-Beclin1 (1:1000, 11306-1-AP, Proteintech), anti-p62 (1:1000, abs105873, Absin), anti-LC3 (1:1000, 12741T, Cell Signaling Technology), antiATG5 (1:5000, ab108327, Abcam), anti-IL15 (1:500, A19319, Abclonal), anti-KLF2 (1:3000, A16480, Abclonal), anti-KLF4 (1:1000, A13673, Abclonal), anti-P50 (1:30000, 14220-1-AP, Proteintech), anti-P65 (1:1000, AF5006, Affinity), anti-PCAF (1:2000, AF0231, Affinity), and anti-GAPDH (1:5000, AB0036, Abways) antibodies. ..

    Immunofluorescence:

    Article Title: Multi-omics insights into dietary zinc–mediated reprogramming of the gut–nasal ecosystem in allergic rhinitis
    Article Snippet: .. As mentioned previously , the prepared 4μm nasal mucosal and colon sections were incubated with primary antibodies including anti-p65 (80979-1-RR, diluted 1:350, proteintech), anti-GPR43 (19952-1-AP, diluted 1:350, proteintech), anti-ZO-1 (ER41204, diluted 1:1,500, huabio), and anti-Occludin (ET1701-76, diluted 1:500, huabio), and then added with corresponding secondary IgG (SA00003-2, diluted 1:350, proteintech), subjected to immunofluorescence (IF) analysis. .. Images were acquired using a Apexview APX100 all-in-one microscope (Olympus, Japan) and a shengqiang SQS-120P Slide Scanner (shengqiang, China).

    Article Title: Isthmin 1 for treatment of lung inflammation
    Article Snippet: Primary antibodies used for immunohistochemistry: anti-MMP-12 (ab66157, Abcam), anti-MMP-9 (ab38898, Abcam), anti-TGF-β31 (V, Santa Cruz Biotechnology), anti-VEGF-A (A-20, Santa Cruz Biotechnology), anti-ISM1 (for mouse lung: E-20, Santa Cruz Biotechnology; for human lung: custom antibody 3M8, AbMart), anti-GRP78 (A-10, Santa Cruz Biotechnology), anti-His-probe (H-15, Santa Cruz Biotechnology), anti-Cleaved caspase-3 (Asp175, Cell Signaling Technology). .. Primary antibodies used for immunofluorescence: anti-ISM1 (E-20, Santa Cruz Biotechnology), anti-p65 (10745-1-AP, Proteintech), anti-CD68 (M-20, Santa Cruz Biotechnology), anti-His-probe (H-15, Santa Cruz Biotechnology), anti-GRP78 (A-10, Santa Cruz Biotechnology), anti-Cleaved caspase-3 (Asp175, Cell Signaling Technology), anti-SP-C (FL-197, Santa Cruz Biotechnology), anti-PCNA (PC10, Santa Cruz Biotechnology), anti-GRP78 (A-10, Santa Cruz Biotechnology), Neutrophil Marker (NIMP-R14, Santa Cruz Biotechnology). .. Reactive oxygen species was measured using OxiSelectTM In Vitro ROS/RNS Assay (STA-347, Cell Biolabs) according to manufacturer's protocol.

    Membrane:

    Article Title: Autophagy promotes the brain metastasis of cisplatin-resistant lung cancer cells through the KLF4/KLF2/IL15 signaling pathway.
    Article Snippet: .. The membrane was blocked and incubated with the following diluted primary antibodies overnight at 4°C: anti-Beclin1 (1:1000, 11306-1-AP, Proteintech), anti-p62 (1:1000, abs105873, Absin), anti-LC3 (1:1000, 12741T, Cell Signaling Technology), antiATG5 (1:5000, ab108327, Abcam), anti-IL15 (1:500, A19319, Abclonal), anti-KLF2 (1:3000, A16480, Abclonal), anti-KLF4 (1:1000, A13673, Abclonal), anti-P50 (1:30000, 14220-1-AP, Proteintech), anti-P65 (1:1000, AF5006, Affinity), anti-PCAF (1:2000, AF0231, Affinity), and anti-GAPDH (1:5000, AB0036, Abways) antibodies. ..

    other:

    Article Title: Isthmin 1 for treatment of lung inflammation
    Article Snippet: Wild-type mice (FVB/NTac, C57BL/6J, and BALB/cAnNTac; 6 to 8 weeks of age) were purchased from InVivos Pte Ltd, Singapore.

    Marker:

    Article Title: Isthmin 1 for treatment of lung inflammation
    Article Snippet: Primary antibodies used for immunohistochemistry: anti-MMP-12 (ab66157, Abcam), anti-MMP-9 (ab38898, Abcam), anti-TGF-β31 (V, Santa Cruz Biotechnology), anti-VEGF-A (A-20, Santa Cruz Biotechnology), anti-ISM1 (for mouse lung: E-20, Santa Cruz Biotechnology; for human lung: custom antibody 3M8, AbMart), anti-GRP78 (A-10, Santa Cruz Biotechnology), anti-His-probe (H-15, Santa Cruz Biotechnology), anti-Cleaved caspase-3 (Asp175, Cell Signaling Technology). .. Primary antibodies used for immunofluorescence: anti-ISM1 (E-20, Santa Cruz Biotechnology), anti-p65 (10745-1-AP, Proteintech), anti-CD68 (M-20, Santa Cruz Biotechnology), anti-His-probe (H-15, Santa Cruz Biotechnology), anti-GRP78 (A-10, Santa Cruz Biotechnology), anti-Cleaved caspase-3 (Asp175, Cell Signaling Technology), anti-SP-C (FL-197, Santa Cruz Biotechnology), anti-PCNA (PC10, Santa Cruz Biotechnology), anti-GRP78 (A-10, Santa Cruz Biotechnology), Neutrophil Marker (NIMP-R14, Santa Cruz Biotechnology). .. Reactive oxygen species was measured using OxiSelectTM In Vitro ROS/RNS Assay (STA-347, Cell Biolabs) according to manufacturer's protocol.



    Similar Products

    95
    Bioss anti nfκb p65 p s536 antibody
    OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), <t>p‐p65</t> (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.
    Anti Nfκb P65 P S536 Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+p65/NFKB+p65(Ser536)+Polyclonal+Antibody/pmc13672686-210-8-25
    Average 95 stars, based on 1 article reviews
    anti nfκb p65 p s536 antibody - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    99
    Cell Signaling Technology Inc tbk1
    OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), <t>p‐p65</t> (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.
    Tbk1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+p65/Phospho-NF-kappaB+p65+(Ser536)+Rabbit+mAb/pm42892647-235-50-51
    Average 99 stars, based on 1 article reviews
    tbk1 - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc p65
    OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), <t>p‐p65</t> (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.
    P65, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+p65/NF-kappaB+p65+Rabbit+mAb/pm42892647-235-42-43
    Average 96 stars, based on 1 article reviews
    p65 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    99
    Cell Signaling Technology Inc p nf κb p65 ser536
    OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), <t>p‐p65</t> (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.
    P Nf κb P65 Ser536, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+p65/Phospho-NF-kappaB+p65+(Ser536)+Rabbit+mAb/pm42888446-183-18-21
    Average 99 stars, based on 1 article reviews
    p nf κb p65 ser536 - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    Cell Signaling Technology Inc phospho nf κb p65
    ( A ) KEGG enrichment analysis of down-regulated DEGs in Sik2 F/F ; LysM Cre cardiac macrophages on day 3 post-MI. The top 20 enriched pathways are listed. ( B ) DEGs (fold change ≥ 2 and P .adjust ≤ 0.05) overlapped in top 20 of enriched pathways. ( C ) Transcription factor prediction was performed using TRRUST databases. The top 10 transcription factors are listed. ( D ) Immunoblotting analysis and quantification of <t>P65</t> in the cytoplasm and nucleus of WT and SIK2-knockout PMs and treated with TNF-α (20 ng/ml) or vehicle ( n = 4) for 1 hour. ( E ) qPCR analysis of Il-1β , Il-6 , Nos2 , Cxcl-1 , and Mmp-9 mRNA expression in WT and SIK2-knockout PMs stimulated with TNF-α for 24 hours ( n = 6). ( F ) qPCR analysis of Il-1β , Il-6 , Nos2 , Cxcl-1 , and Mmp-9 mRNA expression ( n = 6). PMs were pretreated with ARN3236 (3 μmol) and stimulated with TNF-α for 24 hours. ( G ) WikiPathways enrichment analysis of differentially phosphorylated proteins in PMs treated with ARN3236 (3 μmol) or control. The top 20 enriched pathways are listed. ( H ) Immunoblotting analysis and quantification of phosphorylated P65 (p-P65), P65, phosphorylated P38 (p-P38), and P38 expression in WT and SIK2-knockout PMs stimulated with TNF-α or vehicle ( n = 6). ( I and J ) Flow cytometry analysis of efferocytosis in WT or LeSik2 Raw264.7 cells [stimulated with SB 203580 (10 μmol) or not] treated with CFSE-prelabeled RBCs ( n = 6).
    Phospho Nf κb P65, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+p65/Phospho-NF-kappaB+p65+(Ser536)+Rabbit+mAb/pmc13674512-352-33-39
    Average 99 stars, based on 1 article reviews
    phospho nf κb p65 - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    Cell Signaling Technology Inc nf κb p65
    ( A ) KEGG enrichment analysis of down-regulated DEGs in Sik2 F/F ; LysM Cre cardiac macrophages on day 3 post-MI. The top 20 enriched pathways are listed. ( B ) DEGs (fold change ≥ 2 and P .adjust ≤ 0.05) overlapped in top 20 of enriched pathways. ( C ) Transcription factor prediction was performed using TRRUST databases. The top 10 transcription factors are listed. ( D ) Immunoblotting analysis and quantification of <t>P65</t> in the cytoplasm and nucleus of WT and SIK2-knockout PMs and treated with TNF-α (20 ng/ml) or vehicle ( n = 4) for 1 hour. ( E ) qPCR analysis of Il-1β , Il-6 , Nos2 , Cxcl-1 , and Mmp-9 mRNA expression in WT and SIK2-knockout PMs stimulated with TNF-α for 24 hours ( n = 6). ( F ) qPCR analysis of Il-1β , Il-6 , Nos2 , Cxcl-1 , and Mmp-9 mRNA expression ( n = 6). PMs were pretreated with ARN3236 (3 μmol) and stimulated with TNF-α for 24 hours. ( G ) WikiPathways enrichment analysis of differentially phosphorylated proteins in PMs treated with ARN3236 (3 μmol) or control. The top 20 enriched pathways are listed. ( H ) Immunoblotting analysis and quantification of phosphorylated P65 (p-P65), P65, phosphorylated P38 (p-P38), and P38 expression in WT and SIK2-knockout PMs stimulated with TNF-α or vehicle ( n = 6). ( I and J ) Flow cytometry analysis of efferocytosis in WT or LeSik2 Raw264.7 cells [stimulated with SB 203580 (10 μmol) or not] treated with CFSE-prelabeled RBCs ( n = 6).
    Nf κb P65, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+p65/NF-kappaB+p65+XP+Rabbit+mAb/pmc13674512-352-40-43
    Average 99 stars, based on 1 article reviews
    nf κb p65 - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    95
    ABclonal Biotechnology phosphorylated nfκb p65
    ( A ) KEGG enrichment analysis of down-regulated DEGs in Sik2 F/F ; LysM Cre cardiac macrophages on day 3 post-MI. The top 20 enriched pathways are listed. ( B ) DEGs (fold change ≥ 2 and P .adjust ≤ 0.05) overlapped in top 20 of enriched pathways. ( C ) Transcription factor prediction was performed using TRRUST databases. The top 10 transcription factors are listed. ( D ) Immunoblotting analysis and quantification of <t>P65</t> in the cytoplasm and nucleus of WT and SIK2-knockout PMs and treated with TNF-α (20 ng/ml) or vehicle ( n = 4) for 1 hour. ( E ) qPCR analysis of Il-1β , Il-6 , Nos2 , Cxcl-1 , and Mmp-9 mRNA expression in WT and SIK2-knockout PMs stimulated with TNF-α for 24 hours ( n = 6). ( F ) qPCR analysis of Il-1β , Il-6 , Nos2 , Cxcl-1 , and Mmp-9 mRNA expression ( n = 6). PMs were pretreated with ARN3236 (3 μmol) and stimulated with TNF-α for 24 hours. ( G ) WikiPathways enrichment analysis of differentially phosphorylated proteins in PMs treated with ARN3236 (3 μmol) or control. The top 20 enriched pathways are listed. ( H ) Immunoblotting analysis and quantification of phosphorylated P65 (p-P65), P65, phosphorylated P38 (p-P38), and P38 expression in WT and SIK2-knockout PMs stimulated with TNF-α or vehicle ( n = 6). ( I and J ) Flow cytometry analysis of efferocytosis in WT or LeSik2 Raw264.7 cells [stimulated with SB 203580 (10 μmol) or not] treated with CFSE-prelabeled RBCs ( n = 6).
    Phosphorylated Nfκb P65, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+p65/Phospho-NF-kB+p65-S276+Rabbit+pAb/pm42882508-96-28-32
    Average 95 stars, based on 1 article reviews
    phosphorylated nfκb p65 - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    99
    Cell Signaling Technology Inc nf κb p65 d14e12
    ( A ) KEGG enrichment analysis of down-regulated DEGs in Sik2 F/F ; LysM Cre cardiac macrophages on day 3 post-MI. The top 20 enriched pathways are listed. ( B ) DEGs (fold change ≥ 2 and P .adjust ≤ 0.05) overlapped in top 20 of enriched pathways. ( C ) Transcription factor prediction was performed using TRRUST databases. The top 10 transcription factors are listed. ( D ) Immunoblotting analysis and quantification of <t>P65</t> in the cytoplasm and nucleus of WT and SIK2-knockout PMs and treated with TNF-α (20 ng/ml) or vehicle ( n = 4) for 1 hour. ( E ) qPCR analysis of Il-1β , Il-6 , Nos2 , Cxcl-1 , and Mmp-9 mRNA expression in WT and SIK2-knockout PMs stimulated with TNF-α for 24 hours ( n = 6). ( F ) qPCR analysis of Il-1β , Il-6 , Nos2 , Cxcl-1 , and Mmp-9 mRNA expression ( n = 6). PMs were pretreated with ARN3236 (3 μmol) and stimulated with TNF-α for 24 hours. ( G ) WikiPathways enrichment analysis of differentially phosphorylated proteins in PMs treated with ARN3236 (3 μmol) or control. The top 20 enriched pathways are listed. ( H ) Immunoblotting analysis and quantification of phosphorylated P65 (p-P65), P65, phosphorylated P38 (p-P38), and P38 expression in WT and SIK2-knockout PMs stimulated with TNF-α or vehicle ( n = 6). ( I and J ) Flow cytometry analysis of efferocytosis in WT or LeSik2 Raw264.7 cells [stimulated with SB 203580 (10 μmol) or not] treated with CFSE-prelabeled RBCs ( n = 6).
    Nf κb P65 D14e12, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+p65/NF-kappaB+p65+XP+Rabbit+mAb/pm42888446-183-38-41
    Average 99 stars, based on 1 article reviews
    nf κb p65 d14e12 - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    96
    Proteintech anti p65 rabbit antibody

    Anti P65 Rabbit Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+p65/NF-%CE%BAB+p65+Polyclonal+antibody/pmc13657245-66-0-4
    Average 96 stars, based on 1 article reviews
    anti p65 rabbit antibody - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology p nf ĸb p65

    P Nf ĸb P65, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+p65/p-NF%CE%BAB+p65+Antibody/pm42874730-142-24-30
    Average 96 stars, based on 1 article reviews
    p nf ĸb p65 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    Image Search Results


    OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), p‐p65 (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.

    Journal: Advanced Science

    Article Title: Intratumoral Fusogenic Outer Membrane Vesicles Enhance Antitumor Immunity Through Tumor MHC‐I Upregulation and Tumor Bacterization

    doi: 10.1002/advs.78279

    Figure Lengend Snippet: OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), p‐p65 (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.

    Article Snippet: AF647‐conjugated anti‐Escherichia coli LPS antibody (Cat. No. bs‐8000R‐AF647), anti‐NFκB p65 (p‐S536) antibody (Cat. No. bs‐0982R), and anti‐Hexokinase 2 antibody (Cat. No. bs‐9455R) were obtained from Bioss (China).

    Techniques: Expressing, Flow Cytometry, Analysis, Control, RNA Sequencing, Western Blot

    ( A ) KEGG enrichment analysis of down-regulated DEGs in Sik2 F/F ; LysM Cre cardiac macrophages on day 3 post-MI. The top 20 enriched pathways are listed. ( B ) DEGs (fold change ≥ 2 and P .adjust ≤ 0.05) overlapped in top 20 of enriched pathways. ( C ) Transcription factor prediction was performed using TRRUST databases. The top 10 transcription factors are listed. ( D ) Immunoblotting analysis and quantification of P65 in the cytoplasm and nucleus of WT and SIK2-knockout PMs and treated with TNF-α (20 ng/ml) or vehicle ( n = 4) for 1 hour. ( E ) qPCR analysis of Il-1β , Il-6 , Nos2 , Cxcl-1 , and Mmp-9 mRNA expression in WT and SIK2-knockout PMs stimulated with TNF-α for 24 hours ( n = 6). ( F ) qPCR analysis of Il-1β , Il-6 , Nos2 , Cxcl-1 , and Mmp-9 mRNA expression ( n = 6). PMs were pretreated with ARN3236 (3 μmol) and stimulated with TNF-α for 24 hours. ( G ) WikiPathways enrichment analysis of differentially phosphorylated proteins in PMs treated with ARN3236 (3 μmol) or control. The top 20 enriched pathways are listed. ( H ) Immunoblotting analysis and quantification of phosphorylated P65 (p-P65), P65, phosphorylated P38 (p-P38), and P38 expression in WT and SIK2-knockout PMs stimulated with TNF-α or vehicle ( n = 6). ( I and J ) Flow cytometry analysis of efferocytosis in WT or LeSik2 Raw264.7 cells [stimulated with SB 203580 (10 μmol) or not] treated with CFSE-prelabeled RBCs ( n = 6).

    Journal: Science Advances

    Article Title: SIK2 antagonizes postinfarction cardiac repair by driving macrophage proinflammatory and impairing efferocytosis

    doi: 10.1126/sciadv.adw6624

    Figure Lengend Snippet: ( A ) KEGG enrichment analysis of down-regulated DEGs in Sik2 F/F ; LysM Cre cardiac macrophages on day 3 post-MI. The top 20 enriched pathways are listed. ( B ) DEGs (fold change ≥ 2 and P .adjust ≤ 0.05) overlapped in top 20 of enriched pathways. ( C ) Transcription factor prediction was performed using TRRUST databases. The top 10 transcription factors are listed. ( D ) Immunoblotting analysis and quantification of P65 in the cytoplasm and nucleus of WT and SIK2-knockout PMs and treated with TNF-α (20 ng/ml) or vehicle ( n = 4) for 1 hour. ( E ) qPCR analysis of Il-1β , Il-6 , Nos2 , Cxcl-1 , and Mmp-9 mRNA expression in WT and SIK2-knockout PMs stimulated with TNF-α for 24 hours ( n = 6). ( F ) qPCR analysis of Il-1β , Il-6 , Nos2 , Cxcl-1 , and Mmp-9 mRNA expression ( n = 6). PMs were pretreated with ARN3236 (3 μmol) and stimulated with TNF-α for 24 hours. ( G ) WikiPathways enrichment analysis of differentially phosphorylated proteins in PMs treated with ARN3236 (3 μmol) or control. The top 20 enriched pathways are listed. ( H ) Immunoblotting analysis and quantification of phosphorylated P65 (p-P65), P65, phosphorylated P38 (p-P38), and P38 expression in WT and SIK2-knockout PMs stimulated with TNF-α or vehicle ( n = 6). ( I and J ) Flow cytometry analysis of efferocytosis in WT or LeSik2 Raw264.7 cells [stimulated with SB 203580 (10 μmol) or not] treated with CFSE-prelabeled RBCs ( n = 6).

    Article Snippet: Primary antibodies used to specifically detect the proteins of interest were as follows: SIK2 (6919s, CST), GAPDH (G9545, Sigma-Aldrich), α-SMA (A5228, Sigma-Aldrich), Collagen I (AB765P, Sigma-Aldrich), Collagen III (AB7778, Abcam), CD31 (3528s, CST), Phospho-NF-κB P65 (Ser 536 ) (3033s, CST), NF-κB P65 (8242s, CST), Phospho-P38 MAPK (Thr 180 /Tyr 182 ) (4511s, CST), P38 MAPK (8690s, CST), α-Tubulin (66031-1, Proteintech), Histone H3 (68345-1, Proteintech), NOS2 (13120s, CST), FLAG-Tag (14793s, CST), HA-Tag (3724s, CST), TRAF1 (4710s, CST), TRAF2 (4724s, CST), TRAF4 (18527s, CST), TRAF6 (67591s, CST), His-Tag (12698s, CST), and Myc-Tag (2276s, CST).

    Techniques: Analysis, Western Blot, Knock-Out, Expressing, Control, Flow Cytometry, Significance Assay

    ( A ) Venn diagram delineating the intersection of SIK2-binding protein candidates in the top enriched pathways identified in , that is, NF-κB signaling pathway and MAPK signaling pathway. LC-MS/MS, liquid chromatography–tandem mass spectrometry. ( B ) Top proteins interacting with SIK2 identified through mass spectrometry analysis of peptides pulled down using anti-Flag antibody in HEK293T cells transfected with Flag-Sik2. ( C ) Immunoprecipitation in HEK293T cells transfected with Flag-Sik2 using anti-Flag antibody, followed by immunoblotting with corresponding antibodies. HA, hemagglutinin. ( D and E ) Immunoprecipitation in HEK293T cells transfected with Flag-Sik2 and HA-Traf2 using anti-Flag (D) or anti-HA (E) antibody, followed by immunoblotting with corresponding antibodies. FL, full length. ( F ) Immunoprecipitation (IP) in HEK293T cells cotransfected with HA-Traf2 and truncated Flag-Sik2 using an anti-HA antibody, followed by immunoblotting (IB) with corresponding antibodies. ( G ) Immunoprecipitation in HEK293T cells cotransfected with Flag-Sik2 and truncated HA-Traf2 using an anti-HA antibody, followed by immunoblotting with corresponding antibodies. ( H ) Western blotting analysis and quantification of SIK2, TRAF2, p-P38, P38, p-P65, and P65 expression in HEK293T cells transfected with SIK2 and si-TRAF2 or control ( n = 4). ( I ) Coimmunoprecipitation (Co-IP) analysis of TRAF2 ubiquitination in HEK293T cells cotransfected with HA-Traf2 and His-Ub, along with Flag-Sik2 or Flag-Sik2 T175A mutant. ( J ) Co-IP analysis of TRAF2 ubiquitination in HEK293T cells cotransfected with HA-Traf2 and Flag-Sik2, along with Myc-K48-Ub or Myc-K63-Ub. ( K ) Co-IP analysis of TRAF2 phosphate serine (p-Ser) and phosphate threonine (p-Thr) in HEK293T cells transfected with HA-Traf2, along with Flag-Sik2 or Flag-Sik2 T175A mutant.

    Journal: Science Advances

    Article Title: SIK2 antagonizes postinfarction cardiac repair by driving macrophage proinflammatory and impairing efferocytosis

    doi: 10.1126/sciadv.adw6624

    Figure Lengend Snippet: ( A ) Venn diagram delineating the intersection of SIK2-binding protein candidates in the top enriched pathways identified in , that is, NF-κB signaling pathway and MAPK signaling pathway. LC-MS/MS, liquid chromatography–tandem mass spectrometry. ( B ) Top proteins interacting with SIK2 identified through mass spectrometry analysis of peptides pulled down using anti-Flag antibody in HEK293T cells transfected with Flag-Sik2. ( C ) Immunoprecipitation in HEK293T cells transfected with Flag-Sik2 using anti-Flag antibody, followed by immunoblotting with corresponding antibodies. HA, hemagglutinin. ( D and E ) Immunoprecipitation in HEK293T cells transfected with Flag-Sik2 and HA-Traf2 using anti-Flag (D) or anti-HA (E) antibody, followed by immunoblotting with corresponding antibodies. FL, full length. ( F ) Immunoprecipitation (IP) in HEK293T cells cotransfected with HA-Traf2 and truncated Flag-Sik2 using an anti-HA antibody, followed by immunoblotting (IB) with corresponding antibodies. ( G ) Immunoprecipitation in HEK293T cells cotransfected with Flag-Sik2 and truncated HA-Traf2 using an anti-HA antibody, followed by immunoblotting with corresponding antibodies. ( H ) Western blotting analysis and quantification of SIK2, TRAF2, p-P38, P38, p-P65, and P65 expression in HEK293T cells transfected with SIK2 and si-TRAF2 or control ( n = 4). ( I ) Coimmunoprecipitation (Co-IP) analysis of TRAF2 ubiquitination in HEK293T cells cotransfected with HA-Traf2 and His-Ub, along with Flag-Sik2 or Flag-Sik2 T175A mutant. ( J ) Co-IP analysis of TRAF2 ubiquitination in HEK293T cells cotransfected with HA-Traf2 and Flag-Sik2, along with Myc-K48-Ub or Myc-K63-Ub. ( K ) Co-IP analysis of TRAF2 phosphate serine (p-Ser) and phosphate threonine (p-Thr) in HEK293T cells transfected with HA-Traf2, along with Flag-Sik2 or Flag-Sik2 T175A mutant.

    Article Snippet: Primary antibodies used to specifically detect the proteins of interest were as follows: SIK2 (6919s, CST), GAPDH (G9545, Sigma-Aldrich), α-SMA (A5228, Sigma-Aldrich), Collagen I (AB765P, Sigma-Aldrich), Collagen III (AB7778, Abcam), CD31 (3528s, CST), Phospho-NF-κB P65 (Ser 536 ) (3033s, CST), NF-κB P65 (8242s, CST), Phospho-P38 MAPK (Thr 180 /Tyr 182 ) (4511s, CST), P38 MAPK (8690s, CST), α-Tubulin (66031-1, Proteintech), Histone H3 (68345-1, Proteintech), NOS2 (13120s, CST), FLAG-Tag (14793s, CST), HA-Tag (3724s, CST), TRAF1 (4710s, CST), TRAF2 (4724s, CST), TRAF4 (18527s, CST), TRAF6 (67591s, CST), His-Tag (12698s, CST), and Myc-Tag (2276s, CST).

    Techniques: Binding Assay, Liquid Chromatography with Mass Spectroscopy, Liquid Chromatography, Mass Spectrometry, Analysis, Transfection, Immunoprecipitation, Western Blot, Expressing, Control, Co-Immunoprecipitation Assay, Ubiquitin Proteomics, Mutagenesis, Tandem Mass Spectroscopy

    ( A ) KEGG enrichment analysis of down-regulated DEGs in Sik2 F/F ; LysM Cre cardiac macrophages on day 3 post-MI. The top 20 enriched pathways are listed. ( B ) DEGs (fold change ≥ 2 and P .adjust ≤ 0.05) overlapped in top 20 of enriched pathways. ( C ) Transcription factor prediction was performed using TRRUST databases. The top 10 transcription factors are listed. ( D ) Immunoblotting analysis and quantification of P65 in the cytoplasm and nucleus of WT and SIK2-knockout PMs and treated with TNF-α (20 ng/ml) or vehicle ( n = 4) for 1 hour. ( E ) qPCR analysis of Il-1β , Il-6 , Nos2 , Cxcl-1 , and Mmp-9 mRNA expression in WT and SIK2-knockout PMs stimulated with TNF-α for 24 hours ( n = 6). ( F ) qPCR analysis of Il-1β , Il-6 , Nos2 , Cxcl-1 , and Mmp-9 mRNA expression ( n = 6). PMs were pretreated with ARN3236 (3 μmol) and stimulated with TNF-α for 24 hours. ( G ) WikiPathways enrichment analysis of differentially phosphorylated proteins in PMs treated with ARN3236 (3 μmol) or control. The top 20 enriched pathways are listed. ( H ) Immunoblotting analysis and quantification of phosphorylated P65 (p-P65), P65, phosphorylated P38 (p-P38), and P38 expression in WT and SIK2-knockout PMs stimulated with TNF-α or vehicle ( n = 6). ( I and J ) Flow cytometry analysis of efferocytosis in WT or LeSik2 Raw264.7 cells [stimulated with SB 203580 (10 μmol) or not] treated with CFSE-prelabeled RBCs ( n = 6).

    Journal: Science Advances

    Article Title: SIK2 antagonizes postinfarction cardiac repair by driving macrophage proinflammatory and impairing efferocytosis

    doi: 10.1126/sciadv.adw6624

    Figure Lengend Snippet: ( A ) KEGG enrichment analysis of down-regulated DEGs in Sik2 F/F ; LysM Cre cardiac macrophages on day 3 post-MI. The top 20 enriched pathways are listed. ( B ) DEGs (fold change ≥ 2 and P .adjust ≤ 0.05) overlapped in top 20 of enriched pathways. ( C ) Transcription factor prediction was performed using TRRUST databases. The top 10 transcription factors are listed. ( D ) Immunoblotting analysis and quantification of P65 in the cytoplasm and nucleus of WT and SIK2-knockout PMs and treated with TNF-α (20 ng/ml) or vehicle ( n = 4) for 1 hour. ( E ) qPCR analysis of Il-1β , Il-6 , Nos2 , Cxcl-1 , and Mmp-9 mRNA expression in WT and SIK2-knockout PMs stimulated with TNF-α for 24 hours ( n = 6). ( F ) qPCR analysis of Il-1β , Il-6 , Nos2 , Cxcl-1 , and Mmp-9 mRNA expression ( n = 6). PMs were pretreated with ARN3236 (3 μmol) and stimulated with TNF-α for 24 hours. ( G ) WikiPathways enrichment analysis of differentially phosphorylated proteins in PMs treated with ARN3236 (3 μmol) or control. The top 20 enriched pathways are listed. ( H ) Immunoblotting analysis and quantification of phosphorylated P65 (p-P65), P65, phosphorylated P38 (p-P38), and P38 expression in WT and SIK2-knockout PMs stimulated with TNF-α or vehicle ( n = 6). ( I and J ) Flow cytometry analysis of efferocytosis in WT or LeSik2 Raw264.7 cells [stimulated with SB 203580 (10 μmol) or not] treated with CFSE-prelabeled RBCs ( n = 6).

    Article Snippet: Primary antibodies used to specifically detect the proteins of interest were as follows: SIK2 (6919s, CST), GAPDH (G9545, Sigma-Aldrich), α-SMA (A5228, Sigma-Aldrich), Collagen I (AB765P, Sigma-Aldrich), Collagen III (AB7778, Abcam), CD31 (3528s, CST), Phospho-NF-κB P65 (Ser 536 ) (3033s, CST), NF-κB P65 (8242s, CST), Phospho-P38 MAPK (Thr 180 /Tyr 182 ) (4511s, CST), P38 MAPK (8690s, CST), α-Tubulin (66031-1, Proteintech), Histone H3 (68345-1, Proteintech), NOS2 (13120s, CST), FLAG-Tag (14793s, CST), HA-Tag (3724s, CST), TRAF1 (4710s, CST), TRAF2 (4724s, CST), TRAF4 (18527s, CST), TRAF6 (67591s, CST), His-Tag (12698s, CST), and Myc-Tag (2276s, CST).

    Techniques: Analysis, Western Blot, Knock-Out, Expressing, Control, Flow Cytometry, Significance Assay

    ( A ) Venn diagram delineating the intersection of SIK2-binding protein candidates in the top enriched pathways identified in , that is, NF-κB signaling pathway and MAPK signaling pathway. LC-MS/MS, liquid chromatography–tandem mass spectrometry. ( B ) Top proteins interacting with SIK2 identified through mass spectrometry analysis of peptides pulled down using anti-Flag antibody in HEK293T cells transfected with Flag-Sik2. ( C ) Immunoprecipitation in HEK293T cells transfected with Flag-Sik2 using anti-Flag antibody, followed by immunoblotting with corresponding antibodies. HA, hemagglutinin. ( D and E ) Immunoprecipitation in HEK293T cells transfected with Flag-Sik2 and HA-Traf2 using anti-Flag (D) or anti-HA (E) antibody, followed by immunoblotting with corresponding antibodies. FL, full length. ( F ) Immunoprecipitation (IP) in HEK293T cells cotransfected with HA-Traf2 and truncated Flag-Sik2 using an anti-HA antibody, followed by immunoblotting (IB) with corresponding antibodies. ( G ) Immunoprecipitation in HEK293T cells cotransfected with Flag-Sik2 and truncated HA-Traf2 using an anti-HA antibody, followed by immunoblotting with corresponding antibodies. ( H ) Western blotting analysis and quantification of SIK2, TRAF2, p-P38, P38, p-P65, and P65 expression in HEK293T cells transfected with SIK2 and si-TRAF2 or control ( n = 4). ( I ) Coimmunoprecipitation (Co-IP) analysis of TRAF2 ubiquitination in HEK293T cells cotransfected with HA-Traf2 and His-Ub, along with Flag-Sik2 or Flag-Sik2 T175A mutant. ( J ) Co-IP analysis of TRAF2 ubiquitination in HEK293T cells cotransfected with HA-Traf2 and Flag-Sik2, along with Myc-K48-Ub or Myc-K63-Ub. ( K ) Co-IP analysis of TRAF2 phosphate serine (p-Ser) and phosphate threonine (p-Thr) in HEK293T cells transfected with HA-Traf2, along with Flag-Sik2 or Flag-Sik2 T175A mutant.

    Journal: Science Advances

    Article Title: SIK2 antagonizes postinfarction cardiac repair by driving macrophage proinflammatory and impairing efferocytosis

    doi: 10.1126/sciadv.adw6624

    Figure Lengend Snippet: ( A ) Venn diagram delineating the intersection of SIK2-binding protein candidates in the top enriched pathways identified in , that is, NF-κB signaling pathway and MAPK signaling pathway. LC-MS/MS, liquid chromatography–tandem mass spectrometry. ( B ) Top proteins interacting with SIK2 identified through mass spectrometry analysis of peptides pulled down using anti-Flag antibody in HEK293T cells transfected with Flag-Sik2. ( C ) Immunoprecipitation in HEK293T cells transfected with Flag-Sik2 using anti-Flag antibody, followed by immunoblotting with corresponding antibodies. HA, hemagglutinin. ( D and E ) Immunoprecipitation in HEK293T cells transfected with Flag-Sik2 and HA-Traf2 using anti-Flag (D) or anti-HA (E) antibody, followed by immunoblotting with corresponding antibodies. FL, full length. ( F ) Immunoprecipitation (IP) in HEK293T cells cotransfected with HA-Traf2 and truncated Flag-Sik2 using an anti-HA antibody, followed by immunoblotting (IB) with corresponding antibodies. ( G ) Immunoprecipitation in HEK293T cells cotransfected with Flag-Sik2 and truncated HA-Traf2 using an anti-HA antibody, followed by immunoblotting with corresponding antibodies. ( H ) Western blotting analysis and quantification of SIK2, TRAF2, p-P38, P38, p-P65, and P65 expression in HEK293T cells transfected with SIK2 and si-TRAF2 or control ( n = 4). ( I ) Coimmunoprecipitation (Co-IP) analysis of TRAF2 ubiquitination in HEK293T cells cotransfected with HA-Traf2 and His-Ub, along with Flag-Sik2 or Flag-Sik2 T175A mutant. ( J ) Co-IP analysis of TRAF2 ubiquitination in HEK293T cells cotransfected with HA-Traf2 and Flag-Sik2, along with Myc-K48-Ub or Myc-K63-Ub. ( K ) Co-IP analysis of TRAF2 phosphate serine (p-Ser) and phosphate threonine (p-Thr) in HEK293T cells transfected with HA-Traf2, along with Flag-Sik2 or Flag-Sik2 T175A mutant.

    Article Snippet: Primary antibodies used to specifically detect the proteins of interest were as follows: SIK2 (6919s, CST), GAPDH (G9545, Sigma-Aldrich), α-SMA (A5228, Sigma-Aldrich), Collagen I (AB765P, Sigma-Aldrich), Collagen III (AB7778, Abcam), CD31 (3528s, CST), Phospho-NF-κB P65 (Ser 536 ) (3033s, CST), NF-κB P65 (8242s, CST), Phospho-P38 MAPK (Thr 180 /Tyr 182 ) (4511s, CST), P38 MAPK (8690s, CST), α-Tubulin (66031-1, Proteintech), Histone H3 (68345-1, Proteintech), NOS2 (13120s, CST), FLAG-Tag (14793s, CST), HA-Tag (3724s, CST), TRAF1 (4710s, CST), TRAF2 (4724s, CST), TRAF4 (18527s, CST), TRAF6 (67591s, CST), His-Tag (12698s, CST), and Myc-Tag (2276s, CST).

    Techniques: Binding Assay, Liquid Chromatography with Mass Spectroscopy, Liquid Chromatography, Mass Spectrometry, Analysis, Transfection, Immunoprecipitation, Western Blot, Expressing, Control, Co-Immunoprecipitation Assay, Ubiquitin Proteomics, Mutagenesis, Tandem Mass Spectroscopy

    Journal: iScience

    Article Title: M2 type tumor-associated macrophage-derived CCL-18 promotes glioma cell proliferation but does not mediates glioma recurrence after radiotherapy

    doi: 10.1016/j.isci.2026.117695

    Figure Lengend Snippet:

    Article Snippet: Anti-p65 rabbit antibody , Proteintech , 10745-1-AP; RRID: AB_2178878.

    Techniques: Cell-Signaling, Virus, Tissue, Microarray, Recombinant, cDNA Synthesis, Enzyme-linked Immunosorbent Assay, Software, Biomarker Discovery, In Vivo Imaging